| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director | Director, 10% Owner
10 companies
Ecor1 Capital, LLC is a 10% Owner at ADAPY with holdings across 10 companies. Recent SEC Form 4 filings include 16 buys and 7 sells.
Estimated insider holdings value: $1518.4M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | TRAXV First Tracks Biotherapeutics, Inc. | 10% Owner | Sell | 4,705,575 | $13.81 | $64,999,989.71 | -59.7% | - | - | |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | Director | Buy | 2,222,222 | $18.00 | $39,999,996.00 | +89.8% | -22.4% | - | |
| Jul 30, 2025 | 10% Owner | Sell | 64,052,538 | $0.11 | $6,890,235.51 | -15.2% | - | - | ||
| May 19, 2025 | ZYME Zymeworks Inc. | Director, 10% Owner | Buy | 55,421 | $11.47 | $635,585.71 | +0.2% | +18.9% | - | |
| May 6, 2025 | PRTA Prothena Corp Public Ltd Co | 10% Owner | Sell | 6,279,684 | $8.10 | $50,839,807.34 | -23.1% | -5.6% | +52.1% | |
| Apr 17, 2025 | ZYME Zymeworks Inc. | Director, 10% Owner | Buy | 128,713 | $11.32 | $1,456,407.88 | +0.4% | +17.3% | - | |
| Apr 4, 2025 | ZYME Zymeworks Inc. | Director, 10% Owner | Buy | 317,208 | $11.42 | $3,623,970.36 | +0.9% | +19.1% | +136.0% | |
| Apr 2, 2025 | ZYME Zymeworks Inc. | Director, 10% Owner | Buy | 127,415 | $11.75 | $1,497,322.33 | +0.2% | +4.1% | +116.4% | |
| Mar 26, 2025 | ZYME Zymeworks Inc. | Director, 10% Owner | Buy | 97,349 | $12.61 | $1,227,309.18 | +0.3% | +3.8% | +99.9% | |
| Mar 24, 2025 | ZYME Zymeworks Inc. | Director, 10% Owner | Buy | 127,198 | $12.92 | $1,643,247.98 | +0.2% | -4.4% | +80.8% |